```html

Zollinger‑Ellison Disease (Type II)

Overview

Zollinger‑Ellison disease (ZED) is a rare, usually malignant condition in which one or more gastrin‑producing tumors (gastrinomas) form in the pancreas or the duodenum. The excess gastrin stimulates the stomach to produce large amounts of acid, leading to severe peptic ulcer disease and a cascade of gastrointestinal symptoms.

Type II refers to the classification of ZED that is associated with the hereditary syndrome known as **Multiple Endocrine Neoplasia type 1 (MEN‑1)**. Patients with MEN‑1 have a genetic mutation that predisposes them to tumors in the parathyroid glands, pancreatic islet cells, and the pituitary gland, in addition to gastrinomas.

Who it affects: Although ZED can occur at any age, the median age at diagnosis is 45‑55 years. Men are slightly more often affected than women (approximately 1.2:1). In the context of MEN‑1, up to 30 % of affected families develop gastrinomas, making type II the most common form of ZED in hereditary cases.

Prevalence: Overall ZED is estimated at **1–3 cases per million** population per year (NIH). When broken down, isolated (type I) sporadic gastrinomas account for ~70 % of cases, while type II (MEN‑1 associated) accounts for ~20‑30 % and type III (sporadic, non‑MEN‑1, often malignant) for the remainder.

Symptoms

Symptoms arise from two main mechanisms: (1) hyper‑acid secretion causing ulcer disease and (2) mass effect of the tumor. The classic “Zollinger‑Ellison triad” includes refractory peptic ulcer disease, gastric‑acid hypersecretion, and non‑β‑cell pancreatic tumor.

Gastro‑intestinal manifestations

• Refractory peptic ulcers – ulcers that fail to heal after standard therapy; commonly located in the duodenum, jejunum, or even the distal ileum.
• Epigastric or upper‑abdominal pain – often described as burning; worsens on an empty stomach.
• Diarrhea – acid inactivates pancreatic enzymes and damages mucosa, leading to malabsorption.
• Steatorrhea (fatty stools) – result of impaired fat digestion.
• Nausea and vomiting – especially after meals.
• Gastro‑esophageal reflux disease (GERD) – acid overload can cause chronic heartburn.

Systemic & metabolic signs

• Weight loss – due to malabsorption and chronic pain.
• Fatigue – from anemia, nutrient deficiencies, or tumor burden.
• Hypercalcemia – in MEN‑1 patients with concurrent hyperparathyroidism.

Tumor‑related findings

• Abdominal mass – palpable if the tumor is large.
• Jaundice – if a tumor compresses the bile duct.
• Hypoglycemia or hyperglycemia – depending on co‑existing islet‑cell tumors in MEN‑1.

Causes and Risk Factors

Zollinger‑Ellison disease results from **gastrinomas**, neuroendocrine tumors that secrete gastrin. The underlying cause differs between sporadic (type I) and MEN‑1‑related (type II) disease.

Genetic cause – MEN‑1 syndrome

• Autosomal‑dominant inheritance of mutations in the MEN1 gene on chromosome 11q13, which encodes the tumor‑suppressor protein **menin**.
• Loss of menin function leads to unchecked cell growth in endocrine tissue, predisposing to gastrinomas, parathyroid adenomas, and pituitary tumors.

Other risk factors

• Family history of MEN‑1 or ZED.
• Age – most tumors become clinically apparent after the fourth decade.
• Gender – slight male predominance, though MEN‑1 affects both sexes equally.
• Previous gastric surgery – rare case reports suggest altered anatomy may unmask hyper‑acid states, but this is not a primary cause.

Diagnosis

Diagnosis is a stepwise process that combines clinical suspicion, biochemical testing, imaging, and sometimes histologic confirmation.

Biochemical tests

• Fasting serum gastrin level – a level > 1000 pg/mL (or > 5× upper limit) in the presence of gastric acid hypersecretion is highly suggestive. Sensitivity ≈ 85‑95 %.
• Secretin stimulation test – administration of secretin (which normally suppresses gastrin) paradoxically raises gastrin > 120 pg/mL in ZED. Used when fasting gastrin is equivocal.
• Gastric pH measurement – an intragastric pH ≤ 2 confirms acid hypersecretion.
• Chromogranin A (CgA) – a marker of neuroendocrine tumors; elevated in > 70 % of gastrinomas.

Imaging studies

• Contrast‑enhanced CT scan (abdomen/pelvis) – first‑line for tumor localization; detects lesions ≥ 1 cm.
• Magnetic Resonance Imaging (MRI) – superior for liver metastases and soft‑tissue characterization.
• Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT – highly sensitive (up to 95 %) for identifying small or occult gastrinomas due to high somatostatin‑receptor expression.
• Endoscopic ultrasound (EUS) – useful for detecting pancreatic lesions < 1 cm and for guided fine‑needle aspiration.

Histopathology (when surgery is performed)

Biopsy or resection specimens reveal neuroendocrine tumor cells that stain positive for gastrin and chromogranin A. The WHO grading system (based on Ki‑67 index and mitotic rate) predicts aggressiveness.

MEN‑1 evaluation

All patients with type II ZED should undergo genetic counseling and testing for MEN1 mutations, as well as screening for hyperparathyroidism (serum calcium, PTH) and pituitary disease (MRI, hormone panels).

Treatment Options

Treatment aims to control acid hypersecretion, remove or shrink the tumor, and monitor for recurrence or metastasis.

Medical management – acid control

• Proton pump inhibitors (PPIs) – high‑dose omeprazole, esomeprazole, or pantoprazole are first‑line. Doses may be 2–4 times the standard ulcer dose; some patients require lifelong therapy.
• H2‑receptor antagonists – less effective than PPIs but can be added for breakthrough symptoms (e.g., famotidine 40–80 mg daily).
• Antacids – for immediate relief; not a substitute for PPIs.

Close monitoring of serum magnesium, calcium, and vitamin B12 is advised, as chronic PPI use can cause deficiencies.

Surgical options

• Curative resection – enucleation or segmental pancreatectomy for localized gastrinomas (< 2 cm) without metastasis. In MEN‑1, surgery is individualized because of multifocal disease.
• Debulking surgery – removal of > 90 % of tumor burden can reduce acid output and improve symptoms when complete resection is impossible.
• Liver metastasectomy – indicated when hepatic lesions are limited and resectable.

Targeted therapies for unresectable or metastatic disease

• Somatostatin analogs (octreotide LAR, lanreotide) – inhibit gastrin release and may shrink tumors; useful in controlling symptoms and disease progression.
• Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE delivers radiation directly to somatostatin‑receptor‑positive cells; demonstrated improved progression‑free survival in neuroendocrine tumors (NETTER‑1 trial).
• mTOR inhibitor (everolimus) – approved for progressive, well‑differentiated pancreatic NETs; can be considered when other options fail.
• Cytotoxic chemotherapy (streptozocin‑based regimens) – reserved for high‑grade, rapidly progressive disease.

Lifestyle and supportive measures

• Small, frequent meals low in fat to reduce acid stimulus.
• Avoidance of smoking, alcohol, and NSAIDs, which aggravate ulcer disease.
• Calcium‑ and vitamin D supplementation if PPI therapy leads to hypocalcemia.
• Regular bone‑density testing in MEN‑1 patients with hyperparathyroidism.

Living with Zollinger‑Ellison Disease (type II)

Managing a chronic condition that requires high‑dose medications and periodic surveillance can be overwhelming. The following practical tips can help patients maintain a good quality of life.

Medication adherence

• Take PPIs **30 minutes before breakfast** (or as prescribed) to maximize acid suppression.
• Use a pill‑organizer and set daily alarms.
• Keep a medication log and bring it to every appointment.

Nutrition

• Consume a **balanced diet rich in complex carbohydrates, lean protein, and non‑acidic fruits/vegetables**.
• Limit caffeine, carbonated beverages, and spicy foods, which can exacerbate reflux.
• Consider a low‑fat diet (≤ 20 % of calories) to reduce pancreatic enzyme demand.
• If steatorrhea persists, discuss pancreatic enzyme replacement with your gastroenterologist.

Regular monitoring

• Serum gastrin & gastric pH every 6‑12 months while on therapy.
• Imaging (CT/MRI or Ga‑68 DOTATATE PET) every 1‑2 years, or sooner if symptoms change.
• MEN‑1 surveillance: annual calcium, PTH, prolactin, IGF‑1, and pituitary MRI every 3‑5 years.

Psychosocial support

• Join support groups (e.g., NET Patient Foundation) to connect with others facing neuroendocrine tumors.
• Seek counseling if anxiety or depression arises from chronic illness.
• Inform employers and educators about the need for medication timing and occasional medical appointments.

Travel and emergencies

• Carry a **medical alert card** stating “Zollinger‑Ellison disease – high‑dose PPI therapy” and list current medications.
• Pack a 7‑day supply of PPIs in case of lost luggage.
• Know the nearest hospital with gastroenterology/endocrinology services when traveling abroad.

Prevention

Because most gastrinomas arise from genetic mutations, primary prevention is limited. However, certain actions can **reduce disease burden** and **detect complications early**:

• Genetic counseling for families with known MEN‑1 mutations; cascade testing can identify at‑risk relatives.
• Screen at‑risk individuals (first‑degree relatives) with fasting gastrin levels and imaging beginning at age 10‑15 years, per MEN‑1 guidelines (NIH, 2022).
• Avoid known ulcer‑aggravating agents (NSAIDs, excessive alcohol) which can worsen symptoms once gastrinoma develops.

Complications

If left untreated or inadequately controlled, ZED can lead to serious, sometimes life‑threatening problems:

• Refractory or perforated peptic ulcer – risk of peritonitis, sepsis, and need for emergent surgery.
• Gastrointestinal bleeding – from ulcer erosion into vessels; may present as melena or hematemesis.
• Upper‑GI obstruction – due to scarring or tumor mass effect.
• Malabsorption & nutritional deficiencies – iron, calcium, fat‑soluble vitamins (A, D, E, K).
• Metastatic disease – liver is the most common site; can cause hepatic dysfunction and portal hypertension.
• MEN‑1 associated complications – primary hyperparathyroidism (kidney stones, osteoporosis), pituitary adenomas (visual field defects, hormonal excess).
• Reduced quality of life – chronic pain, anxiety, and frequent medical visits.

When to Seek Emergency Care

---

Sources: Mayo Clinic, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), American College of Gastroenterology guidelines, National Comprehensive Cancer Network (NCCN) Neuroendocrine Tumor guidelines, WHO Classification of Tumours of the Digestive System (2023), and peer‑reviewed articles from The New England Journal of Medicine and Journal of Clinical Endocrinology & Metabolism.

```